Frank Celia, Contributing Editor

Despite the buzz around digital media channels, pharma continues to pour marketing dollars into television

Drug-based therapies for opioid dependency gain acceptance and reimbursement

New industry entrants aim at expanding patient volumes even while drug compounding limits some therapy classes